{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:30:14Z","timestamp":1793943014927,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000648","name":"King's College Cambridge, University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.radonc.2026.111800","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:45:22Z","timestamp":1790783122000},"page":"111800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-231X","authenticated-orcid":false,"given":"Luca","family":"Visani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Becherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-5691","authenticated-orcid":false,"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-9971","authenticated-orcid":false,"given":"Sara","family":"Alkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-8461","authenticated-orcid":false,"given":"Angelika M.","family":"Starzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-279X","authenticated-orcid":false,"given":"Liesbeth J.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Stobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Spanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-3345","authenticated-orcid":false,"given":"Clare M.","family":"Isacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-4964","authenticated-orcid":false,"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-1869","authenticated-orcid":false,"given":"Orit","family":"Kaidar-Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-5332","authenticated-orcid":false,"given":"Andrea","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-2096","authenticated-orcid":false,"given":"Birgitte","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-2293","authenticated-orcid":false,"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-2895","authenticated-orcid":false,"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111800_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.6770","article-title":"Effect of radiotherapy on painful bone metastases","volume":"3","author":"McDonald","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00031","article-title":"Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03 AVATAR): a phase II prospective Multicenter Trial","author":"David","year":"2025","journal-title":"JCO Oncology Advances"},{"key":"10.1016\/j.radonc.2026.111800_b0015","article-title":"Stereotactic radiosurgery in the management of brain metastases: a case-based radiosurgery society practice guideline","volume":"9","author":"Ladbury","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijrobp.2020.08.013","article-title":"Single- and multifraction stereotactic radiosurgery dose\/volume tolerances of the brain","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111800_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0030","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0045","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2026.111800_b0060","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0065","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0070","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0080","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111800_b0100","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.21873\/anticanres.12598","article-title":"SN-38 acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced Up-regulation of HIF-1alpha","volume":"38","author":"Okuno","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2026.111800_b0105","doi-asserted-by":"crossref","first-page":"13019","DOI":"10.1038\/ncomms13019","article-title":"Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize","volume":"7","author":"Adams","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2026.111800_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110060","article-title":"Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)","volume":"195","author":"Kaidar-Person","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0115","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111800_b0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.radonc.2026.111800_b0125","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111800_b0130","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111800_b0135","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.radonc.2026.111800_b0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111800_b0145","series-title":"Kadcyla (trastuzumab emtansine): EPAR \u2013 Product Information","author":"Agency","year":"2013"},{"key":"10.1016\/j.radonc.2026.111800_b0150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-014-2500-2","article-title":"Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates","volume":"74","author":"Lu","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2026.111800_b0155","series-title":"Enhertu (trastuzumab deruxtecan): EPAR \u2013 Product Information","author":"Agency","year":"2024"},{"key":"10.1016\/j.radonc.2026.111800_b0160","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.radonc.2026.111800_b0165","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111800_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU\u2010132), an anti\u2010Trop\u20102\u2010SN\u201038 antibody\u2010drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111800_b0175","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.3390\/curroncol30100654","article-title":"Correlation of high-sensitivity cardiac troponin i values and cardiac radiation doses in patients with left-sided breast cancer undergoing hypofractionated adjuvant radiotherapy with concurrent anti-HER2 therapy","volume":"30","author":"Antunac","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0180","article-title":"Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13058-025-02151-1","article-title":"Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study","volume":"27","author":"Azhar","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.radonc.2026.111800_b0190","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000001135","article-title":"Concurrent use of trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: a single-center experience and review of the literature","volume":"47","author":"Bouziane","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2022.12.002","article-title":"Acute skin radiation toxicity seen with concurrent T-DM1: a single institutional report of 35 patients","volume":"67","author":"Dastgheyb","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111800_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104691","article-title":"Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort","volume":"85","author":"Visani","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111800_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.07.1300","article-title":"Multicenter retrospective analysis of the safety and efficacy of sacituzumab govitecan combined with radiation therapy: the French attention study","author":"Alati","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111800_b0210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study","volume":"168","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111800_b0215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","article-title":"Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases","volume":"10","author":"Khatri","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.radonc.2026.111800_b0220","article-title":"Local therapy for isolated central nervous system progression among patients receiving antibody-drug conjugate therapy","volume":"10","author":"Lebow","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf229","article-title":"Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study","volume":"30","author":"Ippolito","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2026.111800_b0230","article-title":"Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer","volume":"80","author":"Debbi","year":"2025","journal-title":"The TENDANCE multicentric French study Breast"},{"key":"10.1016\/j.radonc.2026.111800_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091649","article-title":"The safety and efficacy of the combination of sacituzumab govitecan and palliative radiotherapy-a retrospective multi-center cohort study","volume":"16","author":"Krug","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111800_b0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0000000000001195","article-title":"Safety and tolerability of concurrent radiotherapy and sacituzumab govitecan in metastatic breast cancer","volume":"48","author":"Loap","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110461","article-title":"Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery","volume":"199","author":"Chun","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0250","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11060-025-05230-7","article-title":"Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report","volume":"175","author":"Khatri","year":"2025","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111800_b0255","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","article-title":"Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases","volume":"11","author":"Grinda","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.radonc.2026.111800_b0260","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.canrad.2024.07.019","article-title":"Safety of concurrent trastuzumab-emtansine and radiation therapy for breast cancer: single-centre experience from a morbidity and mortality review meetings procedure","volume":"28","author":"Bennassi","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.radonc.2026.111800_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2021.12.173","article-title":"Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): a phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer","volume":"113","author":"Bellon","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111800_b0270","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-022-04055-y","article-title":"Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer","volume":"159","author":"Id Said","year":"2022","journal-title":"J Neurooncol"},{"issue":"13","key":"10.1016\/j.radonc.2026.111800_b0280","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-2851","article-title":"Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4","volume":"25","author":"Stumpf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2026.111800_b0285","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12885-021-07971-w","article-title":"Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases","volume":"21","author":"Mills","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111800_b0290","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/neuonc\/not329","article-title":"Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema","volume":"16","author":"Carlson","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","article-title":"Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases","volume":"157","author":"Jacot","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111800_b0300","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000769","article-title":"adjuvant trastuzumab emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast cancer: single-center preliminary results","volume":"43","author":"Zolcs\u00e1k","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111800_b0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-016-2265-z","article-title":"Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer","volume":"131","author":"Geraud","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111800_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.radonc.2026.111800_b0315","doi-asserted-by":"crossref","DOI":"10.1093\/abt\/tbaf004","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.radonc.2026.111800_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2026.111800_b0325","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Research : BCR"},{"key":"10.1016\/j.radonc.2026.111800_b0330","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.671","article-title":"Antibody\u2013drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:14:08Z","timestamp":1793942048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":66,"alternative-id":["S0167814026006407"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111800","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111800"}}